Published in Annu Rev Immunol on January 01, 2005
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A (2007) 6.44
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med (2008) 4.70
Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci U S A (2011) 3.55
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol (2009) 2.87
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
New insights into the development of lymphoid tissues. Nat Rev Immunol (2010) 2.64
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes (2008) 2.25
Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat Immunol (2010) 2.08
Modifier loci condition autoimmunity provoked by Aire deficiency. J Exp Med (2005) 2.08
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A (2008) 1.85
Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes (2009) 1.78
IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A (2008) 1.74
IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther (2013) 1.66
Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 1.66
Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes (2008) 1.63
Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A (2012) 1.60
Influence of microbial environment on autoimmunity. Nat Immunol (2009) 1.59
How defects in central tolerance impinge on a deficiency in regulatory T cells. Proc Natl Acad Sci U S A (2005) 1.55
Restoration of the unfolded protein response in pancreatic β cells protects mice against type 1 diabetes. Sci Transl Med (2013) 1.55
Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes (2009) 1.53
Th1-Th17 cells contribute to the development of uropathogenic Escherichia coli-induced chronic pelvic pain. PLoS One (2013) 1.53
Alteration of intra-pancreatic target-organ specificity by abrogation of Aire in NOD mice. J Clin Invest (2006) 1.52
Enhanced thymic selection of FoxP3+ regulatory T cells in the NOD mouse model of autoimmune diabetes. Proc Natl Acad Sci U S A (2007) 1.51
Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J Exp Med (2005) 1.50
The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes (2013) 1.46
Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol (2008) 1.44
Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infection. Infect Immun (2006) 1.38
Control of central and peripheral tolerance by Aire. Immunol Rev (2011) 1.37
Regulatory B cells in autoimmune diseases. Cell Mol Immunol (2013) 1.36
NKG2D in NK and T cell-mediated immunity. J Clin Immunol (2005) 1.32
Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J Immunol (2009) 1.25
Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am J Pathol (2011) 1.21
Sjögren's syndrome: studying the disease in mice. Arthritis Res Ther (2011) 1.21
Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev (2009) 1.19
Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. J Immunol (2009) 1.18
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes (2009) 1.18
Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci U S A (2006) 1.17
T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol (2009) 1.16
The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin Exp Immunol (2010) 1.14
Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol (2008) 1.14
Autoimmunity's next top models. Nat Med (2012) 1.14
Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J Clin Invest (2010) 1.13
Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes (2012) 1.13
A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes. Immunity (2014) 1.11
Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes (2011) 1.11
Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J Immunol (2008) 1.11
Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes (2010) 1.10
Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes (2008) 1.10
Genome-wide end-sequenced BAC resources for the NOD/MrkTac() and NOD/ShiLtJ() mouse genomes. Genomics (2009) 1.10
Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology (2007) 1.09
Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells. Proc Natl Acad Sci U S A (2012) 1.09
Systemic impact of intestinal helminth infections. Mucosal Immunol (2014) 1.08
Inflammasome activation in obesity-related inflammatory diseases and autoimmunity. Discov Med (2011) 1.08
Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice. J Immunol (2010) 1.07
Gut microbiota, probiotics and diabetes. Nutr J (2014) 1.06
Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol (2011) 1.06
Regulatory T cells in experimental autoimmune disease. Springer Semin Immunopathol (2006) 1.06
Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy (2010) 1.06
Ly6C(low) monocytes differentiate into dendritic cells and cross-tolerize T cells through PDL-1. J Immunol (2009) 1.06
Suppression of autoimmune diabetes by soluble galectin-1. J Immunol (2009) 1.06
The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes (2011) 1.05
Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest (2006) 1.05
Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta (2014) 1.04
T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes. Immunology (2010) 1.01
Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun (2012) 1.01
Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the diabetes prevention trial-type 1 (DPT-1). Diabetes (2008) 1.01
B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 1.00
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice. J Immunol (2013) 1.00
Can exposure to environmental chemicals increase the risk of diabetes type 1 development? Biomed Res Int (2015) 0.99
Rotavirus infection accelerates type 1 diabetes in mice with established insulitis. J Virol (2008) 0.99
PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes (2012) 0.99
Protection against or triggering of Type 1 diabetes? Different roles for viral infections. Expert Rev Clin Immunol (2011) 0.99
IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J Immunol (2008) 0.98
Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes. J Immunol (2010) 0.97
Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med (2011) 0.97
Idd9/11 genetic locus regulates diabetogenic activity of CD4 T-cells in nonobese diabetic (NOD) mice. Diabetes (2008) 0.97
Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically. Am J Pathol (2007) 0.96
Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes (2011) 0.96
Virus-induced autoimmune diabetes in the LEW.1WR1 rat requires Iddm14 and a genetic locus proximal to the major histocompatibility complex. Diabetes (2009) 0.96
Immune pathways for translating viral infection into chronic airway disease. Adv Immunol (2009) 0.96
Detecting early-warning signals of type 1 diabetes and its leading biomolecular networks by dynamical network biomarkers. BMC Med Genomics (2013) 0.96
Discovery of native autoantigens via antigen surrogate technology: application to type 1 diabetes. ACS Chem Biol (2014) 0.95
MerTK regulates thymic selection of autoreactive T cells. Proc Natl Acad Sci U S A (2009) 0.95
Population dynamics of islet-infiltrating cells in autoimmune diabetes. Proc Natl Acad Sci U S A (2015) 0.94
The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res (2013) 0.94
CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector t-cell inhibition and regulatory T-cell expansion. Diabetes (2008) 0.94
Immune Regulation in T1D and T2D: Prospective Role of Foxp3+ Treg Cells in Disease Pathogenesis and Treatment. Front Endocrinol (Lausanne) (2013) 0.93
New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation. Curr Diab Rep (2014) 0.93
Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats. Autoimmunity (2010) 0.93
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13
CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73
Murine pancreatic islet isolation. J Vis Exp (2007) 1.68
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67
A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63
Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61
Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55
IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54
The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45
Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol (2013) 1.42
Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39
Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29
Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp (2007) 1.28
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28
Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27
The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med (2011) 1.26
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol (2002) 1.25
Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol (2003) 1.25
Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25
CTLA-4 and tolerance: the biochemical point of view. Immunol Res (2003) 1.24
Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol (2013) 1.24
The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol (2002) 1.24
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23
Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2003) 1.20
T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol (2009) 1.16
Inability to induce tolerance through direct antigen presentation. Am J Transplant (2002) 1.16
Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol (2008) 1.14
The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol (2002) 1.13
MicroRNA regulation of T-cell differentiation and function. Immunol Rev (2013) 1.13
Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol (2011) 1.12
Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol (2007) 1.11
Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes (2010) 1.10
MicroRNA 10a marks regulatory T cells. PLoS One (2012) 1.09
Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol (2005) 1.09
CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol (2003) 1.06
B7-independent inhibition of T cells by CTLA-4. J Immunol (2005) 1.05
microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol (2013) 1.05
Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest (2006) 1.05
Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol (2005) 1.04
Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One (2010) 1.03
Mechanisms of tolerance. Immunol Rev (2011) 1.01
Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol (2007) 1.00
B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 1.00
The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp (2003) 1.00